CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Thymic peptidesbiological
Likely dose
Thymic peptides 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04771013
NCT04771013Phase 2Completed
CompareCT.gov

A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras

Universidad Católica de Honduras·interventional·Posted Feb 25, 2021·Updated Feb 4, 2022

In Brief

A Phase 2 clinical trial evaluating Thymic peptides for COVID-19. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesHonduras
CollaboratorsPontificia Universidad Catolica de Chile

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 25, 2021
Enrollment StartFeb 10, 2021
Primary CompletionMay 14, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.4 years ago

Interventions

Thymic peptidesbiological

250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.